Veterinary Medicines

Veloxa Forte Chewable Tablets for Dogs

Authorised
  • Febantel
  • Pyrantel
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Veloxa Forte Chewable Tablets for Dogs
Veloxa vet 525 mg/504 mg/175 mg Tuggtablett
Active substance:
  • Febantel
  • Pyrantel
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    525.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription except for some pack sizes
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Lavet Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lavet Kft.
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 47992
Date of authorisation status change:
Reference member state:
  • Hungary
Procedure number:
  • HU/V/0116/002
Concerned member states:
  • Austria
  • Belgium
  • Finland
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 12/12/2025
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 12/12/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 12/12/2025
Download